China Pharma Holdings (CPHI) Enterprise Value (2010 - 2026)

China Pharma Holdings (CPHI) has reported Enterprise Value for 17 consecutive years, with $26.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 407.09% year-over-year to $26.4 million; the trailing twelve-month figure through Jun 2026 stood at $26.4 million (up 407.09% YoY), and the FY2025 full-year result was $4.8 million, up 41.19% from the prior year.
• Enterprise Value rose to $26.4 million in Q2 2026 per CPHI's latest filing, from $15.4 million in the prior quarter.
• Across five years, Enterprise Value topped out at $26.4 million in Q2 2026 and bottomed at $586148.8 in Q3 2023.
• Historically, Enterprise Value has averaged $6.6 million across 5 years, with a median of $4.6 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value tumbled 86.85% in 2023, then surged 497.38% in 2024.
• Over 5 years, Enterprise Value stood at $3.0 million in 2022, then plunged by 79.3% to $623221.9 in 2023, then jumped by 450.92% to $3.4 million in 2024, then surged by 41.19% to $4.8 million in 2025, then jumped by 445.43% to $26.4 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $26.4 million, $15.4 million, and $4.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.